Abemaciclib: Difference between revisions
New page: <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treat... |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | ||
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.[ | Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.<ref name="a3">PMID:26264704</ref> See also [https://en.wikipedia.org/wiki/Abemaciclib Abemaciclib]. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||